Literature DB >> 6419312

The role of the microcolony mode of growth in the pathogenesis of Pseudomonas aeruginosa infections.

J W Costerton, J Lam, K Lam, R Chan.   

Abstract

In nature Pseudomonas aeruginosa grows in two modes, the mobile "swarmer" cell and the glycocalyx-enclosed microcolony. The microcolony mode is numerically dominant perhaps because it provides adhesion in a favorable niche and protection from bacteriophages and phagocytic predators. When this organism colonizes the compromised human host, a broad spectrum of different types of infection is produced, ranging from asymptomatic persistent cystitis to the overwhelming bacteremia seen in neutropenic patients. These infections differ radically both in their degree of toxicity and invasiveness and in their susceptibility to control with specific antibodies and/or antibiotics. These differences may reflect the degree to which intact host defense mechanisms force the bacteria to adopt the defensive, microcolony mode of growth. As examples, the nearly intact host defense mechanisms and vigorous immune response of patients with cystic fibrosis force P. aeruginosa in pulmonary infections into a demonstrably cryptic, microcolony mode of growth that allows its persistence in the face of specific antibodies and antibiotics but limits its toxic activity and its dissemination. In contrast, the ruined defense mechanisms of burned skin allow the spread of bacteria in the mobile mode; toxic effects are seen in neighboring tissues, and a mixed mobile-microcolony reservoir population, whose mobile members can subsequently invade the circulatory system, is built up in the burned tissue. Thus, it is important to define the mode of bacterial growth in each type of P. aeruginosa infection and, where the microcolony mode is predominant, to understand the chemistry of the enveloping exopolysaccharide in order to limit its synthesis and/or facilitate its penetration by antibodies and antibiotics.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6419312     DOI: 10.1093/clinids/5.supplement_5.s867

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  22 in total

1.  Biofilms 2003: emerging themes and challenges in studies of surface-associated microbial life.

Authors:  Matthew R Parsek; Clay Fuqua
Journal:  J Bacteriol       Date:  2004-07       Impact factor: 3.490

Review 2.  Establishment of aging biofilms: possible mechanism of bacterial resistance to antimicrobial therapy.

Authors:  H Anwar; J L Strap; J W Costerton
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

Review 3.  Testing the susceptibility of bacteria in biofilms to antibacterial agents.

Authors:  H Anwar; M K Dasgupta; J W Costerton
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

4.  Use of slime dispersants to promote antibiotic penetration through the extracellular polysaccharide of mucoid Pseudomonas aeruginosa.

Authors:  C A Gordon; N A Hodges; C Marriott
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

Review 5.  Bacterial signaling ecology and potential applications during aquatic biofilm construction.

Authors:  Leticia M Vega; Pedro J Alvarez; Robert J C McLean
Journal:  Microb Ecol       Date:  2013-11-26       Impact factor: 4.552

6.  Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  S Jalal; O Ciofu; N Hoiby; N Gotoh; B Wretlind
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

7.  Control of Pseudomonas aeruginosa in the lung requires the recognition of either lipopolysaccharide or flagellin.

Authors:  Reuben Ramphal; Viviane Balloy; Jeevan Jyot; Amrisha Verma; Mustapha Si-Tahar; Michel Chignard
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

8.  Pseudomonas aeruginosa cystic fibrosis isolates of similar RAPD genotype exhibit diversity in biofilm forming ability in vitro.

Authors:  Elena Deligianni; Sally Pattison; Daniel Berrar; Nigel G Ternan; Richard W Haylock; John E Moore; Stuart J Elborn; James S G Dooley
Journal:  BMC Microbiol       Date:  2010-02-08       Impact factor: 3.605

9.  Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection.

Authors:  C Beaulac; S Clément-Major; J Hawari; J Lagacé
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

10.  Role of mutation in Pseudomonas aeruginosa biofilm development.

Authors:  Tim C R Conibear; Samuel L Collins; Jeremy S Webb
Journal:  PLoS One       Date:  2009-07-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.